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The adult stem cell secretome is currently under investigation as an alternative to cell-based therapy in regenerative medicine,
thanks to the remarkable translational opportunity and the advantages in terms of handling and safety. In this perspective, we
recently demonstrated the eﬃcient performance of the adipose-derived mesenchymal stem/stromal cell (ASC) secretome in
contrasting neuroinﬂammation in a murine model of diabetic neuropathy, where the administration of factors released by
dermal ﬁbroblasts (DFs) did not exert any eﬀect. Up to now, the complex mixture of the constituents of the conditioned
medium from ASCs has not been fully deepened, although its appropriate characterization is required in the perspective of
a clinical use. Herein, we propose the diﬀerential proteomic approach for the identiﬁcation of the players accounting for
the functional eﬀects of the cell secretome with the aim to unravel its appropriate applications. Out of 967 quantiﬁed
proteins, 34 and 62 factors were found preponderantly or exclusively secreted by ASCs and DFs, respectively. This
approach led to the recognition of distinct functions related to the conditioned medium of ASCs and DFs, with the
former being involved in the regulation of neuronal death and apoptosis and the latter in bone metabolism and
ossiﬁcation. The proosteogenic eﬀect of DF secretome was validated in vitro on human primary osteoblasts, providing a
proof of concept of its osteoinductive potential. Besides discovering new applications of the cell type-speciﬁc secretome, the
proposed strategy could allow the recognition of the cocktail of bioactive factors which might be responsible for the eﬀects
of conditioned media, thus providing a solid rationale to the implementation of a cell-free approach in several clinical
scenarios involving tissue regeneration.
1. Introduction
Adult stem cell-based therapies have been proven eﬀective in
resolving a wide array of clinical questions, opening the way
to their translation from preclinical models to medical prac-
tice. Up to date, 301 clinical trials explored or are currently
investigating the safety and performance of mesenchymal
stem/stromal cells (MSCs), a class of adult stem cells that
can be conveniently harvested from several tissue sources
(source: http://clinicaltrials.gov, applied ﬁlters: Active, not
recruiting +Terminated+Completed as Recruitment Status,
Interventional (Clinical Trial) as Study Type). Currently,
the therapeutic eﬀect of MSC administration has been tested
for the treatment of numerous acute and chronic pathologies,
spanning from cardiovascular disorders to musculoskeletal
and immune diseases [1, 2]. In the last few years, it has
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become increasingly evident that the beneﬁcial action exerted
by MSCs in these heterogeneous clinical scenarios largely
depends on paracrine mechanisms rather than being a direct
consequence of cell engraftment [3–9]. The therapeutic
potential of the secretome of these cells is currently under
investigation, gathering growing consensus because of the
remarkable translational ability of the cell-free approach that
presents substantial advantages over cell therapy, especially
in terms of handling and safety. In the context of tissue
regeneration, the secretome of MSCs from bonemarrow, adi-
pose tissue, and Warton jelly has been proven eﬀective in
preclinical models of Parkinson’s disease, spinal cord injury,
and ischemic stroke [10, 11], while the one from human
umbilical cord mesenchymal stem/stromal cells has been
proven eﬀective in ameliorating kidney damage and regener-
ating atrophied muscles [12, 13]. Moreover, the eﬀects of
conditioned medium (CM) from cultured MSCs have been
largely explored in multiple biological processes linked to
clinically signiﬁcant events, such as wound healing [14, 15],
inﬂammation blunting [16, 17], angiogenesis [18, 19], and
neuropathic pain [8]. In this scenario, we recently demon-
strated the therapeutic eﬀect of the administration of the
CM from adipose-derived stem/stromal cells (ASCs) in a
mouse model of diabetes mellitus, providing a solid evidence
of its eﬃciency in contrasting neuropathic pain, neuroin-
ﬂammation, and peripheral immune activation [20]. Inter-
estingly, we also established that the observed eﬀects were
speciﬁcally linked to the cell source, as the treatment with
CM derived from dermal ﬁbroblasts (DFs) did not counteract
the monitored symptoms.
Considering the therapeutic potential of the cell secre-
tome, we believe that an appropriate characterization is
required in the perspective of a clinical use. Since it is widely
accepted that the eﬃcacy of the cell secretome is not linked
to a single “ingredient” but depends on a cocktail of factors
acting in synergy, we are currently characterizing theCMcon-
tent, in terms of both soluble components and vesicular car-
gos, by multiple approaches. Recently, we demonstrated that
the extracellular vesicles released by diﬀerentMSCs (i.e., ASCs
and MSCs from bone marrow) and DFs possess peculiar fea-
tures that allow their discrimination through Raman spec-
troscopy with an accuracy of 93.7% [21]. In our previous
in vitro and in vivo works, DFs were chosen as the term of
comparison for MSCs as these cell populations present some
common features, such as stromal localization, phenotypic
proﬁle, and multilineage diﬀerentiative capabilities. Never-
theless, MSCs and DFs diﬀer for important characteristics,
among which the distinct anti-inﬂammatory and angiogenic
potential are particularly interesting in the perspective of their
employment in the regenerative medicine ﬁeld [22, 23]. Here,
we compared the secretome from ASCs to the one from DFs
through a diﬀerential proteomic approach, focusing on its
potential to predict the action of CM deriving from distinct
cell sources on diﬀerent targets and pathological conditions.
We examined the factors diﬀerentially expressed between
the two populations that may be involved in the antineuroin-
ﬂammatory properties of ASCs observed in vivo. Moreover,
on the basis of the factors preponderantly released by dermal
ﬁbroblasts, we hypothesize a proosteogenic eﬀect of CM-DFs
that was validated in vitro with human primary osteoblasts.
2. Materials and Methods
Unless otherwise stated, reagents and chemicals were pur-
chased from Sigma-Aldrich (Saint Louis, MO, USA).
2.1. Cell Culture. All the cell types used in this study were iso-
lated from waste tissues of healthy donors undergoing plastic
(abdominoplasty and liposuction) or orthopaedic surgery,
after written consent and following the procedure PQ
7.5.125, version 4, dated 2015-01-22, approved by the IRCCS
Galeazzi Orthopaedic Institute. ASCs were isolated from the
subcutaneous adipose tissue of 3 female donors (age range:
26–65 y/o) while DFs were isolated from the deepidermised
dermis of 3 female patients (age range: 26–46 y/o). Cells were
isolated following previously described protocols [21].
Brieﬂy, ASCs were isolated from adipose tissue samples fol-
lowing digestion with 0.75mg/ml type I collagenase (250U/
mg, Worthington Biochemical Corporation, Lakewood, NJ,
USA) and ﬁltering of the stromal vascular fraction. DFs were
obtained from fragmented dermis after digestion with 0.1%
type I collagenase. Osteoblasts were isolated from the cancel-
lous bone of a female patient (66 y/o) undergoing total hip
replacement surgery. Brieﬂy, bone fragments were excised
and minced with a scalpel, washed several times in phosphate
buﬀered saline (PBS), and vortexed at high speed in order to
remove residual adipose and/or hematopoietic tissue. Bone
chips were then plated in petri dishes until cell outgrowth.
All cell types were maintained in a humidiﬁed atmosphere
at 37°C, 5% CO2 in complete culture medium (DMEM,
2mM L-glutamine, 50U/ml penicillin, 50μg/ml streptomy-
cin) added with 10% FBS (EuroClone, Milan, Italy). The
medium was replaced every other day and, at 70–80% conﬂu-
ence, cells were detached with 0.5% trypsin/0.2% EDTA,
plated at a density of 10,000 cells/cm2 for ASCs and OBs,
5000 cells/cm2 for DFs, and expanded.
2.2. Conditioned-Media Production. Conditioned medium
was prepared as previously described [20]. Once at 80–90%
conﬂuence, cells at the 4th passage were washed twice with
PBS, kept for one hour in serum-free, phenol-free complete
DMEM, and cultured in the same starving conditions for
72 hours. Conditioned media were then centrifuged at 2500g
for 15 minutes to remove cell debris and concentrated using
Amicon® Ultra-15 centrifugal ﬁlter columns with a 3 kDa
molecular weight cutoﬀ (Merck Millipore, Burlington, MA,
USA). Protein concentration was measured by a Bradford
assay (Bio-Rad Laboratories, Hercules, CA, USA).
2.3. nLC-MS/MS Analysis and Bioinformatics. Conditioned
media samples were delivered to ProMiFa (Protein Microse-
quencing Facility, San Raﬀaele Scientiﬁc Institute, Milan,
Italy) to perform nLC-MS/MS analysis. 20μg of total
proteins from each sample were in-solution digested using
the Filter Aided Sample Preparation (FASP) protocol as
reported in literature [24]. Aliquots of the samples contain-
ing tryptic peptides were desalted using StageTip C18
(Thermo Fisher Scientiﬁc, Waltham, MA, USA) and ana-
lysed by nLC-MS/MS using a Q-Exactive mass spectrometer
(Thermo Fisher Scientiﬁc) equipped with a nanoelectrospray
ion source (Proxeon Biosystems, Odense, Denmark) and a
2 Stem Cells International
nUPLC Easy-nLC 1000 (Proxeon Biosystems). Peptide sepa-
rations occurred on a homemade (75μm i.d., 12 cm long)
reverse phase silica capillary column, packed with 1.9μm
ReproSil-Pur 120 C18-AQ (Dr. Maisch GmbH, Germany).
A gradient of eluents A (distilled water with 0.1% v/v formic
acid) and B (acetonitrile with 0.1% v/v formic acid) was used
to achieve separation (300 nl/min ﬂow rate), from 2% B to
40% B in 88 minutes. Full-scan spectra were acquired with
the lock-mass option, resolution set to 70,000 and mass
range from m/z 300 to 2000Da. The ten most intense
doubly- and triply-charged ions were selected and frag-
mented. All MS/MS samples were analysed using the
Mascot (version 2.6, Matrix Science) search engine to
search the human_proteome 20171122 (93,786 sequences;
37,178,108 residues). Searches were performed with the fol-
lowing settings: trypsin as proteolytic enzyme; 2 missed
cleavages allowed; carbamidomethylation on cysteine as
ﬁxed modiﬁcation; protein N-terminus-acetylation, methio-
nine oxidation as variable modiﬁcations; and mass tolerance
was set to 5 ppm and to 0.02Da for precursor and fragment
ions, respectively. To quantify proteins, the raw data were
loaded into the MaxQuant software version 1.5.2.8 [25].
Label-free protein quantiﬁcation was based on the intensities
of precursors. The experiments were performed in technical
triplicates. The complete dataset of identiﬁed and quantiﬁed
proteins, as obtained by proteomic analysis, was subjected to
Student’s t-test in order to deﬁne signiﬁcantly diﬀerently
expressed proteins with a p value< 0.05, followed by hierar-
chical clustering analysis, using MeV software v. 4_9_0 [26].
2.4. In Vitro Functional Analysis of CM-ASCs and CM-DFs
2.4.1. Cell Viability. 3× 103 osteoblasts/cm2 were plated in
triplicate on 96-well plates and maintained in culture for 16
days in complete culture medium. At days 2, 4, 7, 9, 11, and
14, cells were treated with CM deriving from 10,000 ASCs
or DFs (recipient to donor cell ratio 1 : 10) and viability/pro-
liferation was monitored through time as previously
described [27]. Brieﬂy, at each time point the culture media
were replaced with the addition of 10% alamarBlue®
(Thermo Fisher Scientiﬁc, Waltham, MA, USA) and cells
were incubated for 3.5 hours at 37°C in the dark. 100μl of
supernatant was then transferred to black-bottom 96-well
plates and ﬂuorescence (540 nm excitation λ, 600 nm
emission λ) was read with a Wallac Victor 2 plate reader
(PerkinElmer, Waltham, MA, USA). At the end of the exper-
iment, cells were ﬁxed and stained by Diﬀ-Quik, following
standard protocol (Medion Diagnostics, Miami, FL, USA).
Statistical analysis was performed by two-way ANOVA and
Bonferroni’s multiple comparison test using GraphPad
Prism 5 Software (San Diego, CA, USA).
2.4.2. Real-Time PCR. OBs were plated at a density of 6000
cells/cm2 and cultured in standard conditions until conﬂu-
ence. Then, cells were treated with conditioned medium
deriving from 120,000 ASCs or DFs (recipient to donor cell
ratio 1 : 5). After 24 hours, the expression of osteogenic
marker genes (RUNX2, SPP1, and COLL I) and of VEGF
(recently identiﬁed as a fundamental factor involved in bone
repair and regeneration [28]) was assessed by real-time
polymerase chain reaction (RT-PCR, StepOne Plus, Life
Technologies, Carlsbad, CA, USA) [29]. Brieﬂy, total RNA
was puriﬁed using an RNeasy Mini Kit (Qiagen, Hilden,
Germany). cDNA was obtained by a high-capacity cDNA
reverse transcription kit and ampliﬁed by Single Tube
TaqMan® Gene Expression Assays (RUNX2: hs00231692_m1,
SPP1: hs00959010_m1, VEGF: hs00959010_m1, and COLL I:
hs01076777_m1) (Applied Biosystems, Foster City, CA,
USA). Data were normalized on ACTB (Hs01060665_g1)
and the relative quantiﬁcation was determined using the delta
delta CT (ΔΔCT) method.
2.4.3. Western Blot. OBs were seeded at a density of 8000
cells/cm2 and cultured in standard conditions until conﬂu-
ence. Cells were treated with conditioned medium deriving
from 400,000 ASCs or DFs (recipient to donor cell ratio
1 : 5) for 72 hours. Cells were then lysed in 65mM Tris-
HCl, pH6.8, with 2% sodium dodecyl sulfate (SDS) supple-
mented with protease-inhibitor cocktail. 15μg of whole cell
lysates, quantiﬁed by BCA Protein Assay (Thermo Fisher
Scientiﬁc), were resolved into 8% SDS-PAGE and transferred
to nitrocellulose membranes (GE Healthcare, Little Chalfont,
UK). Membranes were probed overnight with either rabbit
polyclonal antibody raised against osteopontin (OPN;
Abcam, Cambridge, UK) or mouse monoclonal antibody
raised against SPARC (Santa Cruz Biotechnology, Dallas,
TX, USA). Goat polyclonal anti-GAPDH antibody (Santa
Cruz Biotechnology, Dallas, TX, USA) was employed as a
housekeeping protein. Proteins of interest were detected after
45 minutes of incubation with appropriate HRP-conjugated
secondary antibodies (Santa Cruz Biotechnology, Dallas,
TX, USA) using LiteAblot® Turbo Extra-Sensitive Chemilu-
minescent Substrate (EuroClone, Milan, Italy). Images were
acquired through ChemiDoc Imaging System™ and ana-
lysed through Image Lab™ software (Bio-Rad Laboratories,
Hercules, CA, USA).
3. Results
3.1. Diﬀerential Secretome Analysis. We performed a nLC-
MS/MS analysis to identify diﬀerentially secreted proteins
between ASCs and DFs. Three conditioned media of each cell
type were analysed. 1208 proteins were identiﬁed, 976 of
which were quantiﬁed. Following a hierarchical clustering
approach, we identiﬁed two groups of factors that were dif-
ferently secreted among ASCs and DFs (Figure 1(a)). The
results showed that 15 proteins were uniquely or preponder-
antly present in CM-ASCs, while 21 were present in those
from DFs. Using this list as input in the STRING platform
[30], it resulted in the majority of diﬀerently secreted pro-
teins in both groups (9 for ASCs—FDR: 0.00433 and 15 for
DFs—FDR: 4.66e− 07) being associated to extracellular exo-
somes. No relevant functional pathway was associated to
these proteins, even though DF-speciﬁc factors appeared
to be involved in sugar metabolism (monosaccharide
biosynthetic process—FDR: 3.47e− 05, xylulose biosyn-
thetic process—FDR: 0.00461, and nonoxidative branch of
pentose-phosphate shunt—FDR: 0.023).
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Despite that no link to reported pathways was identiﬁed
for the 15 ASC-speciﬁc proteins, several of them have a
known immune function (S100 A13 protein, CCL2, LGMN,
FUCA1, and METRNL) and/or are involved in neuron death
and apoptosis (CCL2, CLU, LGMN, and PCSK5). To widen
our analysis and deepen our understanding of the diﬀeren-
tially secreted proteins, we applied diﬀerent criteria. At ﬁrst,
we manually checked the data to identify factors exclusively
secreted by either ASCs or DFs. Among the proteins released
exclusively by one cell type (4 and 12 for ASCs and DFs,
resp.), some factors were not identiﬁed through the previous
clustering (1 for ASCs and 6 for DFs) (Figure 1(b)). More-
over, applying Student’s t test with no further correction,
we identiﬁed additional factors diﬀerentially secreted from
ASCs (n = 18) and DFs (n = 35). Finally, we compared the
CM of same-donor ASCs and DFs and the factors released
uniquely by one population were manually selected. These
data conﬁrmed that the two cell types peculiarly release a
multitude of diﬀerent factors (31 ASC-speciﬁc proteins and
91 DF-speciﬁc proteins), regardless of the donor features.
However, since many proteins were solely selected with this
criterion (Figure 1(b)), they were not included in further
analyses. Considering the Student’s t test results combined
with cell type-exclusive data, we obtained novel and more
comprehensive lists accounting for 34 (Figure 2) and 62
(Figure 3) factors diﬀerentially or exclusively secreted by
ASCs and DFs, respectively.
These multiple proteins were run in a novel STRING
analysis. Functional enrichment conﬁrmed that the condi-
tioned media of the two cell types contained many diﬀerent
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Figure 1: Diﬀerential proteome analysis of CM-ASCs and CM-DFs. (a) Hierarchical clustering criteria identify 15 proteins preponderantly
secreted by ASCs (n = 3) and 21 factors predominantly released by DFs (n = 3). The color scale represents the label-free quantiﬁcation (LFQ)
of the relative amount of proteins in the biological samples. (b) Venn diagrams (http://bioinfogp.cnb.csic.es/tools/venny) representing the
number of diﬀerentially expressed proteins identiﬁed by distinct statistical analyses (Student’s t test alone (TT) or followed by hierarchical
clustering (HC)) and discrimination criteria (factors uniquely present in the CM of one cell type considering all samples (E) or
considering only ASCs and DFs harvested from the same donor (E (SD)).
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proteins associated to extracellular vesicles (17 proteins for
ASCs—FDR: 3.55e− 05 and 34 proteins for DF—FDR:
7.84e− 13). Moreover, it reinforced the previous observation
that CM-DFs contain proteins involved in metabolic pro-
cesses (Figure 3) and suggested that in CM-ASCs there are
diﬀerent factors regulating endocytosis and cell secretion
(Figure 2). Regeneration functions associated to cell type-
speciﬁc factors were also identiﬁed. In particular, the regula-
tion of neuron death and of neuronal apoptotic properties
were among the ﬁrst 5 results regarding biological processes
associated to ASC factors (Figure 2), consistently with our
preclinical data on neuropathic pain [20]. Diﬀerently, beside
sugar metabolism, several DF factors appeared to have a role
in ossiﬁcation and/or bone metabolism (HNRNPC, MRC2,
RBMX, RRBP1, TNC, and TWSG1, Figure 3). In order to val-
idate this last observation, we performed functional tests on
osteoblasts isolated from a human bone specimen.
3.2. Eﬀects of ASC and DF Secretome on Human Primary
Osteoblasts. As a proof of concept, the involvement of
DF-speciﬁc factors in bone metabolism/ossiﬁcation was
validated by testing the eﬀects of the secretome of same-
donor (46 y/o female donor) ASCs and DFs, on cultured
human primary osteoblasts. At ﬁrst, we investigated the
inﬂuence of CM treatments on osteoblast viability over a
period of two weeks (Figure 4(a)). While the eﬀect of CM-
ASCs was almost undetectable, CM-DFs strongly stimulated
osteoblast viability through time and the lag phase observed
between days 7 and 9 in other groups was avoided. At day
14, we observed a larger number of osteoblasts treated with
CM-DFs with respect to other groups (Figure 4(a), micro-
photographs), demonstrating that this treatment favored cell
proliferation rather than enhancing cell metabolism. Then,
the short-term eﬀect of the secretome on gene expression
was investigated (Figure 4(b)). After 24 hours of treatment,
the levels of RUNX2, SPP1, and VEGF mRNA resulted in
an enhancement by CM-DFs (fold change of 4.1 for RUNX2
and 5.2 for both SPP1 and VEGF), thus supporting our
hypothesis of a proosteoblastic action of CM-DFs. By con-
trast, CM-ASCs reduced the expression of these genes of
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Figure 2: STRING analysis uncovering protein-protein interactions and biological processes associated to the 34 proteins solely or
preponderantly secreted by ASCs.
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Figure 3: STRING analysis uncovering protein-protein interactions and biological processes associated to the 62 proteins solely or
preponderantly secreted by DFs.
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Figure 4: In vitro eﬀect of CM-ASCs and CM-DFs on osteoblasts. (a) Semilog graph representing osteoblast viability assessment at diﬀerent
time points of untreated cells (blue line), cells treated with CM-ASCs (green line), or cells treated with CM-DFs (orange line). The equations
of the exponential functions describing osteoblast growth in the diﬀerent conditions are shown. Data represents the mean± SD of 3 replicates
(diﬀerence versus untreated ∗∗p < 0 01 and ∗∗∗∗p < 0 0001). Microphotographs are representative of cell conﬂuence for each group at the ﬁnal
time point. Scale bars = 100 μm. (b) Relative expression of important osteoblast genes after 24 hours of treatment with CM-ASCs (green bars)
or CM-DFs (orange bars) in respect to untreated cells, by RT-PCR. The mRNA levels of Runt-related transcription factor 2 (RUNX2),
osteopontin (SPP1), vascular endothelial growth factor (VEGF), and type I collagen (COLL I) are represented in relation to β-actin, here
used as a internal control. Data are shown as mean± SD of technical duplicates. (c) Protein expression of extracellular matrix components
by osteoblasts treated with CM-ASCs or CM-DFs for 72 hours. Western blot analysis of osteonectin (SPARC) and osteopontin (OPN)
expression following the treatments. Bands were quantiﬁed by densitometry and normalized on GAPDH.
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about 4 times while COLL I expression was slightly dimin-
ished by both treatments. Finally, we investigated the eﬀect
of a longer CM treatment (72 hours) on the intracellular pro-
tein levels of SPARC and OPN (Figure 4(c)), two important
extracellular matrix components. The stimulating eﬀect of
CM-DFs on osteoblasts was conﬁrmed by a +123% increase
in SPARC expression with respect to untreated cells. How-
ever, a slightly minor upregulation of SPARC was also
induced by CM-ASCs. In addition, a little increase (+29%)
in the naïve 33 kDa form of OPN [31] was also ascribable
to the DF secretome only. Nevertheless, this eﬀect was not
maintained for all the protein isoforms subject to posttrans-
lational modiﬁcations (data not shown).
4. Discussion
In light of the fact that conditioned media could be used in
the future as biotechnological products for regenerative med-
icine, it is essential to carry out their characterization before
proceeding to clinics. Here, we have implemented diﬀerential
proteomics to investigate the secretome of ASCs and DFs,
focusing on the potential applications in the regenerative
medicine ﬁeld. We applied diﬀerent criteria to select proteins
that were diﬀerentially or exclusively released by one cell type
and we came up with 34 and 62 factors uniquely or preva-
lently secreted by ASCs and DFs, respectively. The STRING
analysis of these factors led to the recognition of distinct
functions related to the CM of ASCs and DFs which are con-
sistent with previous ﬁndings on ASC-CM neuroprotective
eﬀects [20, 32–34] and with our current results on DF secre-
tome osteoinductive properties (Figure 4). Several proteins
released more abundantly or exclusively by ASCs, namely
AXL, CCL2, CLU, CRLF1, LGMN, and PCSK9, were found
to be signiﬁcantly associated with the regulation of neuronal
death and apoptosis. These bioactive factors might contrib-
ute to the modulation of neuroinﬂammation exerted by
CM-ASCs in our preclinical models of neuropathic pain
[20, 35] by activating diﬀerent mechanisms. AXL is a recep-
tor tyrosine kinase which regulates the innate immune sys-
tem activation [36] and controls the phagocytosis of dead
neurons. Even though this protein is probably released by
ASCs through exosomes (STRING, Exocarta), it still needs
to be shown whether it is transferred to recipient cells.
Chemokine (C-C motif) Ligand 2 (CCL2) is a pleiotropic
chemokine with an important role in neurogenesis exerted
by promoting glial cell proliferation and growth, inducing
stem cell migration into sites of damage, and directing diﬀer-
entiation of precursor cells into neurons, astrocytes, and oli-
godendrocytes [37]. Clusterin (CLU) is a stress-induced
chaperone involved in neuronal protection [38]. Its levels
are increased in multiple degenerative conditions [39] and
following traumatic brain injury [40]. CLUmodulates neuro-
inﬂammation also thanks to its capacity to suppress comple-
ment activation. Legumain (LGMN) is a cysteine protease
which regulates the development of immune response and
tolerance by playing a key role in the processing of antigens
[41]. Among its functions, the involvement in the axonal
regeneration following spinal cord injury in zebraﬁsh is
particularly intriguing [42]. Finally, the soluble receptor
Cytokine Receptor-Like Factor 1 (CRLF1) and the secreted
protease Proprotein Convertase Subtilisin/Kexin type 9
(PCSK9) may contribute to neuroprotection due to their
activity in promoting neuronal cell survival [43] and in regu-
lating neuronal apoptosis [44], respectively. In addition, two
factors speciﬁcally released only by ASCs could contribute to
the therapeutic action of their CM. Indeed, similarly to
CCL2, CXCL8/IL-8 is known to possess neuroprotective
features [37]. Furthermore, Scrapie Responsive Gene 1
(SCRG1), which is a positive regulator of stem cell self-
renewal, migration, and diﬀerentiation potential [45], has
been recently proposed as an inhibitor of the inﬁltration of
monocytes, dendritic cells, natural killer cells, and chroni-
cally activated T lymphocytes [46]. Other proteins with a
known immune function were highlighted by the hierarchi-
cal clustering analysis. Among them, Alpha-L-Fucosidase 1
(FUCA1) exerts immunoregulatory actions [47], Meteorin-
like protein (METRL) stimulates the expression of anti-
inﬂammatory cytokines [48], and S100 calcium-binding
protein A13 (S100A13) acts as a regulator of macrophage
inﬂammation [49]. Our hypothesis is that all these proteins
concur in the conversion of the proinﬂammatory/neurodes-
tructive environment observed in diabetic mice into an
anti-inﬂammatory/neuroprotective one [20]. Further investi-
gations with CM previously deprived of speciﬁc factors could
conﬁrm their involvement in the neuroinﬂammation blunt-
ing. In any case, our unbiased approach allowed us to identify
neuroprotection as one of the main functions of the ASC
secretome. The modulation of neurodegenerative and neu-
roinﬂammatory diseases by the release of neurotrophic and
immunomodulative molecules is well documented not only
for ASCs but also for other MSCs [10, 33] and it explains
the multitude of applications for MSCs and their conditioned
media in these contexts [20, 32, 35, 50, 51].
On the other hand, the analysis of the factors preponder-
antly or speciﬁcally released by DFs produced unexpected
outcomes. CM-DFs resulted particularly enriched in proteins
involved in sugar metabolism and further investigations
should aim at deciphering whether these factors might be
involved in the production of glycosaminoglycans and/or in
other metabolic processes. Of note, several proteins, which
are involved in bone metabolism and ossiﬁcation (HNRNPC,
MRC2, RBMX, RRBP1, TNC, and TWSG1), were also high-
lighted. Among them, Tenascin C (TNC) is an extracellular
matrix glycoprotein implicated in osteoblastic diﬀerentia-
tion and mineralization within the bone, probably acting
as a mediator of TGF-β-induced new bone formation
[52]. C-type mannose receptor 2 (MRC2, also known as
ENDO180, CD280, or uPARAP) plays a supporting role
in bone development being involved in collagen traﬃcking
and deposition [53]. Another factor involved in collagen
turnover, particularly in its biosynthesis, is Ribosome-
Binding Protein 1 (RRBP1, also known as p180). All these
proteins, together with RBMX (RNA-Binding Motif Protein,
X-Linked) and HNRNPC (Heterogeneous Nuclear Ribonu-
cleoproteins C1/C2), have been reported to be signiﬁcantly
upregulated during the osteogenic diﬀerentiation of MSCs
[54], suggesting their role in osteogenesis. Finally, the
secreted protein Twisted Gastrulation Homolog 1 (TWSG1)
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is known to bind bone morphogenetic proteins and to inﬂu-
ence osteoblast maturation, even though with contrasting
eﬀects [55, 56]. Interestingly, it also inhibits osteoclastogene-
sis [57], supporting a primary role as a bone-building eﬀec-
tor. Since up to now the CM-DF osteoinductive potential
has never been reported, we performed a functional in vitro
test which provided evidence of the proosteogenic function
predicted from the proteomic analysis. In this study,
CM-DFs switched from a term of comparison, convenient
to point out the speciﬁc eﬀectors contained in CM-ASCs,
to an interesting source of bioactive factors. With our
results, we do not want to minimize the proosteogenic
potential of the MSC secretome, which has been already
documented especially for BMSCs [58], but to suggest
novel applications for DFs. In fairness, the potential use
of these cells in supporting tissue regeneration has been
largely investigated, mainly considering their ability to
synthesize and deposit extracellular matrices and release bio-
active molecules [59]. Further investigations will be focused
on assessing the eﬀects of the DF secretome and/or of its sin-
gle components on other cell types.
Interestingly, most of the factors diﬀerentially released by
ASCs and DFs are contained in extracellular vesicles, but
only half of the proteins involved in the regenerative func-
tions are released as vesicular cargos (STRING). This remark
is consistent with recent observations of a major eﬀect
exerted by the whole conditioned medium compared to the
exosomes only [60] (our unpublished observations). Further
studies investigating this issue are strongly recommended
before choosing the proper cell product to be used in speciﬁc
applications.
5. Conclusions
This study provides evidence that the diﬀerential proteomic
analysis constitutes a useful tool to determine the proper
therapeutic target of conditioned media derived from diﬀer-
ent cell types. Our data reinforced previous observations on
the neuroprotective action of the ASC secretome by pointing
out speciﬁc factors involved in this process and identifying an
unexpected proosteogenic aptitude of CM-DFs. This method
might be applied to identify the bioactive factors which are
released by diﬀerent cells and are responsible for the biolog-
ical eﬀect of their conditioned media. At last, a proper valida-
tion of speciﬁc CM factors could pave the way for the future
production of artiﬁcial cocktails of bioactive molecules (a
novel biological medical product) to be used in diﬀerent
regenerative medicine applications.
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